Please login to the form below

Not currently logged in
Email:
Password:

Prevnar

This page shows the latest Prevnar news and features for those working in and with pharma, biotech and healthcare.

Pfizer names next CEO as Read retires

Pfizer names next CEO as Read retires

and an expected continued decline in sales of vaccine Prevnar.

Latest news

  • Pfizer’s Prevnar-13 successor takes aim at Merck rival Pfizer’s Prevnar-13 successor takes aim at Merck rival

    is in pursuit of PCV-15 (also known as V114), a 15-valent candidate that Merck is bringing to market to compete with Pfizer’s established pneumococcal vaccine Prevnar-13, which ... pair. However, it fell a little short in infant studies, failing to

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar ... Vaccines for

  • Pfizer split still on cards - for tax reasons Pfizer split still on cards - for tax reasons

    cancer therapy Ibrance (palbociclib), arthritis therapy Xeljanz (tofacitinib) and Prevnar pneumonia vaccine family. ... Prevnar grew 16% to top $1.5bn in the quarter, helped by a new indication for use in adults, which added $439m as well as a $40m

  • Soaring sales of Pfizer's Prevnar lead to calls for price cut Soaring sales of Pfizer's Prevnar lead to calls for price cut

    Pfizer has reported a hefty increase in sales of its Prevnar family of pneumonia vaccines, prompting medical charities to call for a price cut. ... Aside from Prevnar, rheumatoid arthritis treatment Xeljanz (tofacitinib) also performed well - rising 66%

  • Pfizer falls as strong dollar and generic erosion bites Pfizer falls as strong dollar and generic erosion bites

    Pfizer's global vaccines sales saw the best growth with sales rising 44% to $1.33bn, predominately on the back of the Prevnar family of inoculations. .

More from news
Approximately 5 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    This was driven largely by higher-than-expected sales of its pneumonia vaccine, Prevnar, which accounted for more than 11% of its total revenues in the third quarter of 2017.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics